Trial Profile

Clinical study of 9MW 3911

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 15 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs 9MW 3911 (Primary)
Indications Cancer
Focus Adverse reactions

Most Recent Events

15 Mar 2023 New trial record
03 Mar 2023 According to a Mabwell Therapeutics media release, the clinical trial application for 9MW3911 Injection independently developed by its subsidiary Nanjing NovoAcine Biotechnology Co., Ltd. was accepted by National Medical Products Administration (NMPA) for the indication of advanced malignancies.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com